Patient Benefit and Risk in Anticancer Drug Development: A Systematic Review of the Ixabepilone Trial Portfolio

Benjamin Carlisle, James Mattina, Tiger Zheng, Jonathan Kimmelman
doi: https://doi.org/10.1101/19003467

Article usage

Article usage: August 2019 to January 2025

AbstractFullPdf
Aug 201954021
Sep 20193007
Oct 201936024
Nov 201940013
Dec 201925015
Jan 202047031
Feb 202073031
Mar 2020132046
Apr 2020195043
May 2020108042
Jun 202039038
Jul 202036036
Aug 202037047
Sep 202038049
Oct 202031036
Nov 202022039
Dec 202027034
Jan 2021147446
Feb 2021216133
Mar 2021415542
Apr 2021230132
May 2021450344
Jun 2021763340
Jul 2021771642
Aug 2021742547
Sep 2021398033
Oct 2021341022
Nov 2021281125
Dec 20212018
Jan 20222774
Feb 20221115
Mar 20221544
Apr 20221747
May 202225115
Jun 202222916
Jul 20221514
Aug 20222434
Sep 202235418
Oct 202217010
Nov 202213213
Dec 20222202
Jan 20232215
Feb 20232366
Mar 20232739
Apr 20234928
May 202310310
Jun 2023947
Jul 2023627
Aug 202312010
Sep 20231418
Oct 20231214
Nov 202324113
Dec 20232015
Jan 20241555
Feb 20241106
Mar 20242148
Apr 20241445
May 20241734
Jun 20241877
Jul 2024745
Aug 2024618
Sep 202413811
Oct 20241139
Nov 20241639
Dec 20248111
Jan 2025212
Back to top
Posted August 01, 2019.
Download PDF

Supplementary Material

Data/Code
Email
Patient Benefit and Risk in Anticancer Drug Development: A Systematic Review of the Ixabepilone Trial Portfolio
Benjamin Carlisle, James Mattina, Tiger Zheng, Jonathan Kimmelman
medRxiv 19003467; doi: https://doi.org/10.1101/19003467
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area